All In Biotech

Investigational drug · Phase 3

Enpatoran

Also called: M5049, M5049 dose, Enpatoran dose

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

9

Any phase or sponsor naming "Enpatoran"

First trial start

2022

Mar 31, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Enpatoran", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus (CLE)
  • Systemic Lupus Erythematosus
  • Systematic Lupus Erythematosus
  • Cutaneous Lupus Erythematosus

Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "Enpatoran" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 25 on PubMed

Also in development for Systemic Lupus Erythematosus (SLE)

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • LitifilimabBIIB059Phase 35 trials

    Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • SG301Phase 33 trials

    Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection

  • Descartes-08Phase 24 trials

    Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)

  • ESG206ESG206-2Phase 23 trials

    Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome

  • BCMA-CD19-IL-15Phase 22 trials

    iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)

  • C-CAR168Phase 22 trials

    AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.